A recent study from the Department of Preventive Dentistry, Peking University School and Hospital of Stomatology, Beijing 100081, China; and Department of Periodontics, School of Dental Medicine, Philadelphia shows that “FOXO1 differentially regulates both normal and diabetic wound healing.” This study was published in the 27 April 2015 issue of Journal of Cell Biology (JCB) by Prof Dana T. Graves & Chenying Zhang, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based accelerated healing therapy for Diabetic patients: Agaricus blazei Murill (AbM), a medicinal mushroom, enhances wound healing in diabetic patients via down regulation of its target gene.
This study suggests a small molecule-based wound healing therapy for diabetic patients. Agaricus blazei Murill, by increasing the expression of its target gene, it may: (1) increase TGF-β1 expression and its down stream target genes; (2) increase keratinocyte migration; and (3) promote wound closure. Thereby, it may accelerate wound healing. Thus, pharmacological formulations encompassing “Agaricus blazei Murill” may be used to accelerate would healing.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Natural product-based accelerated healing therapy for Diabetic patients: Agaricus blazei Murill, a medicinal mushroom, enhances wound healing in diabetic patients via down regulation of its target gene, 16/May/2015, 23.04, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
* Research cooperation
Undisclosed information: How Agaricus blazei Murill (AbM) accelerates wound healing in diabetic patients